Recommendations for All Patients
- Providers should offer the options of maternal serum screening (MSS) and diagnostic testing for chromosome aneuploidy to every patient.
- Providers should engage in a discussion with their patients about the benefits, limitations, and risks of MSS and diagnostic testing so that patients may make informed and autonomous decisions.
- If the provider feels a patient would benefit from additional discussion prior to making a decision, a referral to a genetic counselor or other qualified provider may be appropriate.
- Documentation of the patient's decision to elect or to decline screening and testing should be made in the patient's medical record.
- Providers should be aware of factors that may impact the options available to their patients, such as the patient's gestational age, insurance coverage, and access to services and providers.
- An ultrasound to assess the fetal anatomy is suggested at approximately 18w0d to 20w0d gestation for all patients regardless of whether or not they choose to have screening or diagnostic testing.
Recommendations for Low Risk Patients Less Than 14 Weeks of Gestation
- For patients who may consider chorionic villus sampling (CVS) or amniocentesis, stepwise sequential screening or combined first trimester screening should be considered because:
- Both are tailored to fit the needs of patients who desire early detection of chromosome aneuploidy but wish to employ a screening method prior to making a decision about diagnostic testing.
- Both allow for the option of CVS in higher risk pregnancies while deferring testing of lower risk pregnancies to the second trimester without causing increased anxiety.
- Of the screening options that provide risk information in the first trimester, stepwise sequential screening has the highest detection rates for Down syndrome and trisomy 18.
- If CVS is not an option, integrated screening may be considered in order to maximize detection rates.
- If a patient completes combined first trimester screening, a separate second trimester MSS for chromosome aneuploidy is NOT indicated. Screening for chromosome aneuploidy in the second trimester in patients who present prior to 14 weeks should ONLY be performed as a part of integrated, serum integrated, stepwise sequential, or contingency screening. Independent screening in first and second trimesters increases the false positive rate of screening.
- Patients who have an increased nuchal translucency (NT) (≥95th% or ≥3.0 mm) should be offered diagnostic testing by either CVS or amniocentesis. A referral for a fetal echocardiogram should also be considered if the NT ≥3.5 mm.
- Early amniocentesis (prior to 15 weeks of gestation) is not recommended due to the increased risks for pregnancy loss, clubfoot, and fluid leakage. CVS should be offered as the diagnostic testing option for chromosome aneuploidy in the first trimester.
Recommendations for Low Risk Patients After 14 Weeks of Gestation
- Patients who desire MSS but did not have MSS in the first trimester should be offered a quad or penta screen rather than a triple screen due to the increased detection rates.
- Amniocentesis should be offered as the diagnostic testing option for chromosome aneuploidy for patients after 15 weeks of gestation.
Recommendations for Patients at Increased Risk for Chromosome Aneuploidy
- Patients who desire screening information may be offered non-invasive prenatal testing (NIPT) due to the high detection rates and low false positive rates. NIPT should only be offered in the context of informed consent, education, and counseling by a qualified provider, such as a genetic counselor. Standard confirmatory diagnostic testing should be offered as follow-up to positive NIPT results. High risk patients who decline NIPT but remain interested in screening should be made aware of alternate screening options as appropriate based on gestational age and screening availability.
- If the patient presents prior to 14 weeks gestation, CVS and amniocentesis should both be offered as diagnostic testing options for chromosome aneuploidy.
- If the patient presents after 14 weeks gestation, amniocentesis should be offered as the diagnostic testing option for chromosome aneuploidy.
A decision tree for selecting between screening and diagnostic testing options is provided in the original guideline document.
Obstetrics and Gynecology
Advanced Practice Nurses
Allied Health Personnel
Health Care Providers
Psychologists/Non-physician Behavioral Health Clinicians
To provide information that assists physicians and allied health professionals in making decisions about different screening and diagnostic testing for chromosome aneuploidy throughout pregnancy
Pregnant patients who are in the first or second trimester
- Discussion of benefits, limitations, and risks of maternal serum screening
- Referral to genetic counselor
- Documentation of patient's decision to elect or refuse screening
- Ultrasound to assess fetal anatomy
- Chorionic villus sampling (CVS)
- Amniocentesis (early amniocentesis is not recommended)
- Noninvasive prenatal testing
Searches of Electronic Databases
The guideline authors searched via PubMed for articles from 2008 to 2012, but articles from any year were used, including articles from the 1970s and 1980s. Articles on prenatal chromosome testing and screening were used as well as a mix of landmark papers, original research, and reviews in the publication. Specific terms included (but were not limited to): prenatal diagnosis, prenatal screening, chromosome aneuploidy, first trimester screening, integrated screening, contingency screening, stepwise sequential screening, maternal serum screening, ultrasound for chromosome aneuploidy, CVS, amniocentesis, NIPT, NIPD, cell free fetal DNA, and genetic counseling for prenatal testing.
Expert Consensus (Committee)
A formal cost analysis was not performed and published cost analyses were not reviewed.
Internal Peer Review
The type of evidence supporting the recommendations is not specifically stated.
- Appropriate use of prenatal screening and diagnostic testing options for chromosome aneuploidy
- The primary benefit of chorionic villus sampling (CVS) is that it can be performed at an earlier gestational age, allowing for earlier decision-making.
- The primary limitation of screening is that it does not provide a definitive diagnosis, leading to the potential of increased anxiety in women with an unaffected pregnancy and the potential of false reassurance in women who have a pregnancy with a chromosome aneuploidy. Another limitation of screening is the variability in the detection rates, false positive rates, screening cut-offs, and anatomical ultrasound markers included in the screen based on the particular laboratory and/or provider involved. In addition, detection rates for screening in multiple gestations are generally decreased from those of singletons.
- Despite numerous potential benefits associated with screening and testing for chromosome aneuploidy, there are also limitations. Available options may be limited by a number of factors, including: gestational age of the patient at entry into the healthcare system, state regulations impacting available options, insurance coverage and out-of-pocket costs to the patient, laboratory contracts, availability of laboratory draw sites, access to certified nuchal translucency (NT) providers, and access to physicians who perform chorionic villus sampling (CVS) or amniocentesis. One of the main barriers faced in screening is insurance coverage, as each private and public insurance plan has specific requirements for coverage of screening and diagnostic testing for chromosome aneuploidy. Additionally, there is often a time lapse between the publication of guidelines recommending the incorporation of a new test and routine coverage of that test by insurance companies. These issues should be considered when assessing a patient's access to various prenatal screening and diagnostic testing options.
Early amniocentesis (prior to 15 weeks of gestation) is not recommended due to the increased risks for pregnancy loss, clubfoot, and fluid leakage.
- The practice guidelines of the National Society of Genetic Counselors (NSGC) are developed by members of the NSGC to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns, including access to and/or delivery of services. Each practice guideline focuses on a clinical or practice based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within the NSGC practice guidelines reflect the current scientific and clinical knowledge at the time of publication, are only current as of their publication date, and subject to change without notice as advances emerge.
- In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments, and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider's best medical judgment based on the clinical circumstances of a particular patient or patient population. Practice guidelines are published by NSGC for education and informational purposes only, and NSGC does not "approve" or "endorse" any specific methods, practices, or sources of information.
An implementation strategy was not provided.
|Wilson KL, Czerwinski JL, Hoskovec JM, Noblin SJ, Sullivan CM, Harbison A, Campion MW, Devary K, Devers P, Singletary CN. NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. J Genet Couns. 2013 Feb;22(1):4-15. [44 references] PubMed|
Not applicable: The guideline was not adapted from another source.
National Society of Genetic Counselors - Medical Specialty Society
National Society of Genetic Counselors
National Society of Genetic Counselors Practice Guidelines Committee
Authors: K. L. Wilson; J. L. Czerwinski; J. M. Hoskovec; S. J. Noblin; C. M. Sullivan; A. Harbison; M. W. Campion; K. Devary; P. Devers; C. N. Singletary
This is the current release of the guideline.
Electronic copies: Available to subscribers from the Journal of Genetic Counseling Web site .
The following is available:
- Bennett RL, French KS, Resta RG, Doyle DL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns 2008 Oct;17(5):424-33. Available to subscribers from the Journal of Genetic Counseling Web site .
This NGC summary was completed by ECRI Institute on May 28, 2013. The information was verified by the guideline developer on June 18, 2013.
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.
The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.